Initial Statement of Beneficial Ownership (3)
March 23 2020 - 4:38PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
BeiGene, Ltd. |
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/12/2020
|
3. Issuer Name and Ticker or Trading Symbol
LEAP THERAPEUTICS, INC. [LPTX]
|
(Last)
(First)
(Middle)
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
GRAND CAYMAN KY1-1108
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 4804637 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Warrant | (2) | (2) | Common Stock | 4804637.0 | $2.11 | D | |
Explanation of Responses: |
(1) | Common Stock issued on March 12, 2020 upon conversion of Series B Mandatorily Convertible Cumulative Non-Voting Perpetual Preferred Stock. |
(2) | The Warrant is exercisable at any time on or after the issuance date and until January 7, 2027. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
BeiGene, Ltd. C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN KY1-1108 |
| X |
|
|
Signatures
|
BeiGene, Ltd. /s/ Scott A. Samuels, SVP, General Counsel | | 3/23/2020 |
**Signature of Reporting Person | Date |
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Apr 2023 to Apr 2024